Related Experiment Video
Updated: Jan 9, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
4.0K
Innovative Device-Based Treatments for Hypertension
Min Zhang1, Peng Li2,3, Yanhui Sheng1,4
1Department of Cardiology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu, China.
American Journal of Hypertension
|December 4, 2025
Summary
Hypertension affects 1.28 billion globally, increasing risks for stroke and heart disease. Device-based therapies targeting the autonomic nervous system offer new treatment avenues for resistant hypertension.
Area of Science:
- Cardiology
- Nephrology
- Neurology
Background:
- Hypertension prevalence doubled globally between 1990 and 2019, affecting 1.28 billion people.
- Elevated blood pressure (BP) significantly increases risks for stroke, coronary artery disease (CAD), heart failure (HF), and chronic kidney disease (CKD).
- Resistant hypertension (RH) is defined as uncontrolled BP despite multiple antihypertensive medications, necessitating alternative treatment strategies.
Purpose of the Study:
- To review the pathophysiological basis of device-based antihypertensive therapies.
- To critically evaluate the current clinical evidence for these interventions.
- To highlight future directions for device-based therapies in clinical practice.
Main Methods:
- Review of existing literature on device-based antihypertensive therapies.
- Analysis of pathophysiological mechanisms targeting the autonomic nervous system.
- Evaluation of clinical trial data and outcomes.
Main Results:
- Device-based therapies, including renal denervation and baroreceptor activation, primarily target the autonomic nervous system.
- Existing clinical evidence for these interventions is critically evaluated.
- Future research and clinical integration pathways are discussed.
Conclusions:
- Device-based therapies represent a promising frontier for managing resistant hypertension.
- Further research is needed to optimize techniques and confirm long-term efficacy and safety.
- Integration into clinical practice requires robust evidence and standardized protocols.
Related Concept Videos
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
578
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
578
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
888
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
888
01:30Heart Failure V: Medical Management
200
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
200
01:22Heart Failure VI: Adjunct Therapies
235
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
235
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.2K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
418
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
418